Vanguard Group Inc. Sells 287,620 Shares of Natera, Inc. $NTRA
Vanguard Group Inc. reduced its stake in Natera, Inc. by 2.3% in the third quarter, selling 287,620 shares but still owning over 12 million shares valued at approximately $1.99 billion. Meanwhile, other institutional investors like JPMorgan Chase & Co. increased their holdings. Insider selling has also occurred, with CEO Steven Chapman and another insider selling shares, totaling over $103 million in insider sales over the last 90 days.
Cibc World Market Inc. Sells 6,191 Shares of Natera, Inc. $NTRA
CIBC World Market Inc. significantly reduced its stake in Natera, Inc. by selling 6,191 shares, retaining holdings valued at approximately $240,000. This divestment occurred amidst recent heavy insider selling, including Natera's Director and CFO offloading shares worth millions. Despite insider sales, Wall Street analysts maintain a "Moderate Buy" rating for Natera with an average price target of $249.20, with some firms raising targets further.
Assessing Natera (NTRA) Valuation After Launch Of EDEN Preeclampsia Risk Study
Natera (NTRA) recently announced the EDEN study for its non-invasive prenatal screening test for preeclampsia, drawing investor attention to its valuation. While a narrative model suggests the stock is 17.9% undervalued with a fair value of $257, its high Price-to-Sales ratio of 13.8x compared to peers and the industry suggests a tougher picture. Investors should consider the assumptions behind the valuation, potential risks, and Natera's R&D investments balanced against profitability pressures.
Readystate Asset Management LP Invests $12.74 Million in Natera, Inc. $NTRA
Readystate Asset Management LP has disclosed a new position in Natera, Inc. (NASDAQ:NTRA), purchasing 79,155 shares valued at approximately $12.74 million in Q3, representing about 0.06% of the company. Institutional ownership in Natera is notably high at 99.90%, despite significant insider selling totaling over $105 million in the past 90 days. Analysts maintain a "Moderate Buy" consensus with an average price target of $249.20 for Natera.
Natera, Inc. $NTRA Shares Sold by Eagle Health Investments LP
Eagle Health Investments LP significantly reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 13.7% in Q3, selling 32,300 shares. This move contributed to a broader trend of insider selling, with company insiders offloading 450,787 shares worth approximately $105.4 million over the last 90 days. Despite the insider selling, analysts maintain a generally positive outlook on Natera, with a consensus "Moderate Buy" rating and an average price target of $249.20.
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
Natera, Inc. (NASDAQ: NTRA) announced it will release its fourth quarter and full-year results for 2025 on February 26, 2026, after the market closes. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss these financial results. Natera specializes in cell-free DNA and genetic testing for oncology, women’s health, and organ health.
Zweig DiMenna Associates LLC Buys 8,400 Shares of Natera, Inc. $NTRA
Zweig DiMenna Associates LLC has increased its stake in Natera, Inc. by 6.8%, acquiring an additional 8,400 shares and bringing its total holdings to 132,500 shares, valued at approximately $21.33 million. This makes Natera the firm's 15th largest holding, representing about 1.5% of its portfolio. While institutional investors are increasing positions, company insiders have been net sellers, offloading 455,899 shares worth over $106 million in the last 90 days.
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
Natera, Inc. (NASDAQ: NTRA) announced it will release its fourth-quarter and full-year 2025 financial results on February 26, 2026, after market close. The company will also host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Natera specializes in cell-free DNA and genetic testing for oncology, women's health, and organ health.
Natera, Inc. (NTRA) reports preliminary Q4 revenue
Natera, Inc. (NTRA) has released its preliminary revenue figures for the fourth quarter. The company has a market capitalization of $11.53 billion and an average trading volume of 1.13 million shares. This announcement provides an early look at their financial performance.
How (NTRA) Movements Inform Risk Allocation Models
This article analyzes Natera Inc. (NASDAQ: NTRA) focusing on its stock movements to inform risk allocation models. It highlights a positive near-term sentiment within a long-term strong context, despite a mid-term weak bias, and details three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss points. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the stock.
Envestnet Asset Management Inc. Purchases 17,254 Shares of Natera, Inc. $NTRA
Envestnet Asset Management Inc. increased its stake in Natera, Inc. by 10% in the third quarter, acquiring an additional 17,254 shares to own a total of 189,276 shares valued at approximately $30.47 million. Despite this, company insiders have been net sellers, with the CFO selling shares and total insider sales reaching roughly $106.48 million in the last three months. Wall Street analysts maintain a "Moderate Buy" consensus rating for Natera with an average price target of $249.20.
When Will Natera, Inc. (NASDAQ:NTRA) Breakeven?
Analysts predict Natera, Inc. (NASDAQ:NTRA) will break even by 2028, with an expected profit of US$211 million, after posting significant losses in previous years. This breakeven projection relies on a highly optimistic average annual growth rate of 55%. Despite this, the company maintains a judicious capital structure with low debt relative to equity, reducing investment risk.
Natera Inc (NTRA) Trading 3.93% Higher on Feb 9
Natera Inc (NTRA) saw its shares surge by 3.93% in mid-day trading on February 9, reaching an intraday high of $213.49 before closing at $211.03. This places NTRA significantly above its 52-week low but still below its 52-week high. Wall Street analysts maintain an "Outperform" rating with an average target price suggesting a potential upside, although GuruFocus estimates a slight downside based on its GF Value.
Natera's Signatera test to be covered under Medicare
Natera's Signatera test, a molecular residual disease (MRD) test, is now covered under Medicare for patients with breast cancer, expanding its reach as the only molecular recurrence test for this indication. This expanded coverage, facilitated by a finalized local coverage determination (LCD) from Medicare Administrative Contractor Palmetto GBA, is effective for claims with service dates on or after February 12, 2024. The Signatera test is already covered for colorectal and muscle-invasive bladder cancer, and its inclusion for breast cancer solidifies its role in guiding personalized treatment decisions and monitoring for recurrence.
Natera, Inc. $NTRA Shares Sold by Savant Capital LLC
Savant Capital LLC recently decreased its stake in Natera, Inc. (NASDAQ:NTRA) by 20% in the third quarter of 2025, selling 6,243 shares and retaining 24,985 shares valued at approximately $4.02 million. This comes as Natera has seen significant insider selling, with directors selling a total of 455,899 shares worth about $106.5 million in the last 90 days. Despite the insider selling and a missed earnings estimate, analysts maintain a "Moderate Buy" consensus rating for NTRA with an average price target of $249.20.
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Holdings in Natera, Inc. $NTRA
IQ EQ FUND MANAGEMENT IRELAND Ltd significantly increased its stake in Natera, Inc. (NASDAQ:NTRA) by 57.1% during the third quarter, now holding 25,940 shares valued at approximately $4.18 million. Despite this institutional vote of confidence, Natera has seen substantial insider selling, with the CEO and CFO collectively selling shares worth millions in early February, raising questions about future performance. Analysts currently rate NTRA as a "Moderate Buy" with an average target price of $249.20, although the stock's recent performance has been volatile amidst various influential news headlines, including regulatory submissions and ongoing insider transactions.
AGF Management Ltd. Sells 6,300 Shares of Natera, Inc. $NTRA
AGF Management Ltd. reduced its stake in Natera, Inc. (NTRA) by selling 6,300 shares, bringing their total ownership to 7,326 shares valued at $1.18 million. This comes amid significant insider selling from Natera's CEO and other executives, totaling over $106 million in the last quarter, which has lowered insider ownership to 5.63%. Despite the insider and institutional trimming, Natera has a "Moderate Buy" consensus rating from analysts, a potential positive catalyst with a recent FDA submission, and a target price near $249.20.
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
Natera, Inc. has announced the launch of its EDEN study, a large, multi-center prospective study focused on the early risk assessment of preeclampsia and other serious pregnancy complications. The study aims to evaluate Natera's non-invasive prenatal screening test, which combines cell-free DNA, additional analytes, and clinical data, by enrolling up to 7,500 pregnant participants in the United States. This research builds on previous findings linking cfDNA characteristics to adverse pregnancy outcomes and seeks to provide more precise and earlier identification of risks.
Study tracks new noninvasive test to flag dangerous pregnancy complications early
Natera (NASDAQ: NTRA) has announced the launch of its EDEN study, a large-scale, multi-center prospective study involving up to 7,500 pregnant participants. The study aims to evaluate Natera's new non-invasive prenatal screening test for early risk assessment of preeclampsia and other adverse pregnancy outcomes. This next-generation test combines cell-free DNA, additional analytes, and clinical data to identify high-risk pregnancies earlier and with greater precision.
Natera, Inc. $NTRA Shares Purchased by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans significantly increased its stake in Natera, Inc. (NASDAQ:NTRA) by 19.1%, purchasing an additional 10,167 shares, bringing their total to 63,377 shares valued at over $10.2 million. This comes amidst substantial insider selling, with over 455,000 shares worth $106.5 million sold in the last three months, including a notable reduction by CEO Steven Chapman. Despite these insider sales, analysts generally rate NTRA as a "Moderate Buy" with an average target price of $249.20, following Natera's revenue beat but EPS miss in its latest quarterly earnings.
This brand-new Peninsula building sat vacant for a year. Now it's landed two big tenants
The Brittan West building in San Carlos, which had been vacant for a year, has secured two significant tenants, including medical test developer Natera. Natera will occupy a full 62,969-square-foot floor, expanding its presence in the Bay Area. The building was developed by Premia Capital and Prince Street Partners.
Natera Inc: President Moshkevich sells $1.07 million in NTRA stock By Investing.com
Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), sold 4,639 shares of company stock across two days for a total of $1.07 million. These sales were conducted via a Rule 10b5-1 trading plan. The transactions occurred amidst volatility in Natera's stock and after recent positive company developments, including a premarket approval application for its Signatera CDx test and completion of enrollment for a Prospera Heart test trial.
Natera Inc. president Fesko sells $830k in stock
John Fesko, President and Chief Business Officer of Natera Inc. (NASDAQ:NTRA), sold 3,594 shares of his company's stock for a total of $830,278 on February 3, 2026. These transactions were executed to cover tax obligations related to the vesting of Restricted Stock Units and were conducted under a pre-arranged trading plan. Fesko now directly owns 178,081 shares of Natera Inc.
Natera Inc: President Moshkevich sells $1.07 million in NTRA stock
Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), sold 4,639 shares of company stock across February 2-3, 2026, totaling approximately $1.07 million. These transactions were executed under a Rule 10b5-1 trading plan, leaving Moshkevich with direct ownership of 137,847 shares. The sale follows a period of stock volatility for Natera, which despite strong revenue growth, is trading above its fair value according to InvestingPro.
Natera Inc. president Fesko sells $830k in stock
Natera Inc. President and Chief Business Officer John Fesko sold 3,594 shares of company stock worth $830,278 to cover tax obligations related to the vesting of Restricted Stock Units. These sales were conducted under a pre-arranged trading plan. This news follows strong preliminary Q4 2025 results for Natera, including revenue growth and increased test volume, alongside ongoing advancements in their diagnostic technologies.
Natera Inc (NTRA) Stock Price Down 7.82% on Feb 4
Shares of Natera Inc (NTRA) fell 7.82% in mid-day trading on February 4th, reaching an intraday low of $209.43. Wall Street analysts have an average target price of $255.88 for NTRA, indicating a 21.92% upside, with a consensus "Outperform" recommendation. However, GuruFocus estimates the GF Value at $192.55, suggesting an 8.26% downside from the current price.
National Pension Service Invests $1.49 Million in Natera, Inc. $NTRA
National Pension Service has acquired a new stake of 9,272 shares in Natera, Inc., valued at approximately $1.49 million, during the third quarter. This investment is part of significant institutional ownership in Natera, with JPMorgan, Norges Bank, and AQR Capital Management also holding sizable positions. Despite Natera missing EPS estimates in Q3, analysts maintain a "Moderate Buy" rating with an average price target of $249.20.
Trading Systems Reacting to (NTRA) Volatility
This article analyzes Natera Inc. (NASDAQ: NTRA) volatility using AI-driven trading systems, highlighting weak near-term sentiment despite long-term strength. It presents various trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report emphasizes a significant 39.5:1 risk-reward setup targeting an 11.5% gain.
Natera Submits Signatera™ CDx PMA to FDA
Natera, Inc. announced the submission of its premarket approval (PMA) to the FDA for Signatera CDx, a companion diagnostic for detecting molecular residual disease (MRD) in bladder cancer patients. This submission is supported by Phase 3 clinical trial data showing improved disease-free and overall survival for Signatera-positive patients treated with atezolizumab. If approved, Signatera CDx would be the first MRD test to guide treatment decisions in muscle-invasive bladder cancer, addressing a critical need in personalizing therapy for this aggressive cancer.
Natera Files FDA PMA for Signatera CDx in Muscle-Invasive Bladder Cancer
Natera has submitted a Premarket Approval (PMA) application to the U.S. FDA for its Signatera CDx test to detect molecular residual disease (MRD) in muscle-invasive bladder cancer (MIBC) patients. This application aims to identify patients who could benefit from atezolizumab (Tecentriq®) and is supported by data from the randomized, double-blind phase 3 IMvigor011 trial. If approved, Signatera CDx would be a first-in-class companion diagnostic MRD test for bladder cancer, moving MRD-guided treatment into a formal FDA-approved pathway.
FDA premarket approval sought for Signatera CDx test in MIBC
Natera has submitted an application to the FDA for premarket approval of its Signatera CDx test as a companion diagnostic for selecting muscle-invasive bladder cancer (MIBC) patients for adjuvant atezolizumab treatment. This application is supported by phase 3 IMvigor011 trial data, which demonstrated that circulating tumor DNA (ctDNA) can predict which patients benefit from atezolizumab, showing significant improvements in disease-free and overall survival for ctDNA-positive patients. The findings also suggest that ctDNA-negative patients may safely avoid adjuvant treatment.
Natera, Inc. (NASDAQ:NTRA) Receives Average Rating of "Moderate Buy" from Analysts
Eighteen analysts have given Natera, Inc. (NASDAQ:NTRA) a consensus "Moderate Buy" rating with an average 12-month target price of $249.20. While the company exceeded revenue estimates, it missed on EPS, and insider selling has been noted. Natera recently completed enrollment in a key transplant trial.
Natera, Inc. $NTRA Shares Purchased by New York State Common Retirement Fund
The New York State Common Retirement Fund significantly increased its stake in Natera, Inc. ($NTRA) by 63.2% in Q3, now holding 148,247 shares worth about $23.86 million. Institutional ownership of Natera remains high at 99.9%, with major investors like Vanguard and JPMorgan also increasing their positions. However, company insiders have been net sellers, disposing of over half a million shares valued at nearly $115 million in the last quarter, which could create short-term selling pressure.
Short Interest in Natera, Inc. (NASDAQ:NTRA) Declines By 27.2%
Short interest in Natera, Inc. (NASDAQ:NTRA) decreased by 27.2% in January, totaling 3,456,165 shares as of January 15th, representing 2.6% of the stock. Despite significant insider selling worth over $114 million, the company maintains a "Moderate Buy" consensus rating from Wall Street analysts with an average target price near $249. Natera recently completed enrollment in a key heart transplant trial, de-risking its Prospera transplant franchise, while institutional ownership remains very high.
Natera, Inc. $NTRA Shares Purchased by Mirae Asset Global Investments Co. Ltd.
Mirae Asset Global Investments Co. Ltd. increased its holdings in Natera, Inc. by 10.4% in the third quarter, acquiring an additional 6,208 shares, bringing its total to 66,016 shares valued at approximately $10.63 million. Institutional ownership of Natera remains high at 99.9%, though recent insider selling activity, totaling over $114 million in the last 90 days, could exert short-term selling pressure. Natera reported strong Q3 revenue of $592.2 million, surpassing estimates, but missed on EPS, with analysts generally maintaining a "Moderate Buy" rating and a consensus price target of around $249.20.
Natera president sells $528k in NTRA stock
Solomon Moshkevich, Natera's President, Clinical Diagnostics, sold 2,213 shares of NTRA stock across two transactions for approximately $528,853. These sales, conducted under a 10b5-1 plan, were for tax obligations related to vested Restricted Stock Units. Despite the insider sales and an "overvalued" assessment by InvestingPro, the company maintains a "GOOD" financial health rating and recently reported strong preliminary Q4 results with significant revenue growth and advancements in its testing technologies.
Natera CEO sells $1.4m in NTRA stock
Natera CEO Steven Leonard Chapman sold $1.4 million worth of NTRA stock across two transactions on January 27 and 28, totaling 5,970 shares. These sales, executed near the stock's 52-week high, were primarily to cover tax obligations from vested Restricted Stock Units under a pre-arranged 10b5-1 trading plan. The company recently announced strong preliminary Q4 2025 results and several advancements in its testing technologies.
Natera CFO Brophy sells $1.19 million in shares
Michael Burkes Brophy, CFO of Natera, Inc. (NASDAQ:NTRA), sold 4,964 shares of common stock totaling $1.19 million between January 27 and January 29, 2026. These sales, executed under a pre-arranged trading plan, included shares sold to cover tax obligations. Natera recently reported strong preliminary Q4 2025 results and is advancing several clinical trials and AI initiatives.
Natera SEC. Daniel Rabinowitz sells $450k in stock
Daniel Rabinowitz, SEC and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), sold approximately $450,773 worth of company stock through two transactions in late January 2026. These sales, executed under a pre-arranged Rule 10b5-1(c) trading plan, were primarily to cover tax obligations related to vested Restricted Stock Units. Natera recently reported strong preliminary fourth-quarter 2025 results with significant revenue growth and test volume increase, maintaining analyst confidence, and has several ongoing R&D initiatives for its testing platforms.
Natera: President Fesko sells $409k in stock
John Fesko, President and Chief Business Officer of Natera, Inc. (NASDAQ:NTRA), sold 1,712 shares of company stock for a total of $409,127 on January 27 and 28, 2026, to cover tax obligations. This sale occurred as the genetic testing company's stock has surged 64% over the past six months, and the company recently reported strong preliminary fourth-quarter 2025 results. Natera is also advancing in clinical trials for heart transplant rejection monitoring and colorectal cancer detection.
Natera president sells $528k in NTRA stock
Solomon Moshkevich, Natera's President, Clinical Diagnostics, sold 2,213 shares of NTRA common stock for approximately $528,853 through two separate transactions in January 2026. These sales, conducted under a pre-arranged trading plan, were primarily to cover tax obligations related to Restricted Stock Units. Despite these insider sales, Natera exhibits "GOOD" financial health and recently reported strong preliminary fourth-quarter results and promising advancements in its testing technologies.
Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue
Natera, Inc. announced preliminary Q4 2025 revenue of $660 million, surpassing the average forecast, with total 2025 revenue reaching $2.3 billion. The company processed approximately 923,600 tests in Q4, representing a 17% increase year-over-year. CEO Steve Chapman highlighted record gains in women's health, organ health, and oncology, expressing confidence in continued growth through 2026, while TD Cowen maintained a "Buy" rating and raised its price target for NTRA.
Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue
Natera, Inc. (NASDAQ: NTRA) announced preliminary fourth-quarter 2025 revenue of $660 million, surpassing the average forecast, with full-year 2025 revenue reaching $2.3 billion. The company processed approximately 923,600 tests in Q4, a 17% increase from the previous year, driven by strong growth in women’s health, organ health, and oncology. TD Cowen maintained its Buy recommendation and raised its price target for Natera, citing strong fundamentals and a positive outlook for 2026.
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
Natera, Inc. has completed enrollment in its ACES-EMB trial, which evaluates whether its Prospera Heart test can replace invasive biopsies for monitoring heart transplant rejection. This randomized-controlled trial enrolled over 300 patients across 17 U.S. transplant centers and aims to demonstrate the benefits of non-invasive donor-derived cell-free DNA (dd-cfDNA) testing compared to the current biopsy-based standard of care. Positive results could fundamentally change post-transplant care by reducing costly and risky procedures.
Natera (NTRA) Completes Enrollment for Heart Transplant Study
Natera (NTRA) has completed enrollment for its ACES-EMB study, designed to evaluate if its Prospera Heart test can replace invasive biopsies for monitoring heart transplant rejection. The company, a diagnostic and research firm with a $33.52 billion market cap, shows strong revenue growth but negative profitability margins and recent insider selling. Despite these challenges, its financial health appears stable with high liquidity and low debt, and analyst sentiment remains positive.
Natera completes enrollment in heart transplant monitoring trial
Natera, Inc. has completed enrollment for its ACES-EMB trial, which evaluates whether its non-invasive Prospera Heart test can replace traditional biopsies for monitoring heart transplant rejection. This trial, involving over 300 patients across 17 U.S. centers, aims to prove that the Prospera test provides comparable clinical outcomes to invasive methods. The completion of enrollment marks a significant step towards potentially changing the standard of care for heart transplant recipients, offering a less invasive and potentially more cost-effective solution.
Heart biopsy alternative? 300-patient trial of Natera blood test fully enrolled
Natera has completed enrollment for its ACES-EMB trial, which evaluates if its Prospera Heart test can replace invasive biopsies for monitoring heart transplant rejection. This randomized-controlled trial enrolled over 300 patients across 17 U.S. transplant centers, comparing Prospera surveillance to standard biopsy-based care. Successful results could fundamentally change post-transplant care by offering a non-invasive molecular monitoring alternative.
Prospera™ featured in landmark interventional study advancing lung transplant care
Natera's Prospera test was featured in a new prospective clinical trial conducted by The Ohio State University Wexner Medical Center, exploring its potential to reduce the number of invasive biopsies for lung transplant patients. The study found that Prospera-guided monitoring allowed physicians to safely omit the 9-month surveillance biopsy in approximately 75% of low-risk patients without compromising outcomes. These findings suggest that Prospera can improve patient experience and the sustainability of transplant programs by offering more personalized and efficient care.
Natera co-founder Sheena Jonathan sells $365,914 in NTRA stock
Natera co-founder Sheena Jonathan sold $365,914 worth of NTRA stock through multiple transactions on January 23, 2026, under a pre-arranged trading plan. Following these sales, Jonathan still directly holds over 264,000 shares, and associated trusts retain additional shares. This news follows Natera's strong preliminary Q4 2025 results, reporting nearly 40% revenue growth and increased test volumes, leading analysts to maintain positive ratings.
$8.25M Natera prenatal screening class action settlement
Natera has agreed to an $8.25 million class action settlement over allegations that it misrepresented the reliability of its noninvasive prenatal screening tests. The settlement benefits consumers nationwide who paid out-of-pocket for Natera's Panorama or Vasistera tests between specified dates. Class members can claim a financial payment, with varying amounts depending on proof of purchase, by the deadline of March 23, 2026.
